Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Alpelisib in PIK3CA-related overgrowth spectrum (PROS)
NL-OMON60371Phase 2Active, not recruiting
- Sponsor
- Novartis
- Start
- Jan 2022
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised trial in PIK3CA-related overgrowth spectrum (PROS) comparing Alpelisib with Placebo (2 arms). Primary endpoint: Confirmed objective response by BIRC. Started Jan 2022; status: active, not recruiting.
02
Drugs
alpelisib
03
Conditions
PIK3CA-related overgrowth spectrum (PROS)
Beyond the preview
Go deeper on NL-OMON60371.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON60371.